Filtered By:
Cancer: Myeloma
Drug: Dexamethasone

This page shows you your search results in order of date.

Order by Relevance | Date

Total 640 results found since Jan 2013.

Connexin 43 gap junction affects survival and drug resistance of multiple myeloma side population cells
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.10. Epub 2023 Aug 30.ABSTRACTDrug resistance remains a major challenge for multiple myeloma (MM) treatment, and side population (SP) cells may play a key role in this resistance. The function of connexin 43 (Cx43)-mediated gap junction intercellular communication (GJ-IC) in MM cells is poorly understood. Bone marrow mesenchymal stem cells (BMSCs) from different sources were isolated and cultured. SP cells of MM cell line RPMI 8266 were separated by flow cytometry. Real-time reverse transcriptase-polymerase chain reaction and Western blot were used to detect Cx43...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: Z Wang J X Fu X H Zhang Y Sun X P Ge Source Type: research

Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
CONCLUSIONS: This semi-automated analysis was in high agreement with standard approaches for detecting response to MM therapy. This proof-of-concept study suggests that larger studies should be conducted to confirm how FDG PET analysis may aid early response detection in MM.PMID:37657154 | DOI:10.1016/j.tranon.2023.101767
Source: Translational Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Tyler J Wellman Sarah R Mudd Kelly N Godby Dustin W Wooten Jeremy A Ross Orlando F Bueno Danielle Wanik Chaitanya R Divgi Robert A Comley Luciano J Costa Jacob Y Hesterman Source Type: research

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research